SURMOUNT-OSA Topline Results; Abbott Q1 ‘24 Earnings; Lilly Insulin Settlement Dropped; NeuroBo Doses First Patient in Ph1 Obesity Trial
Four cardiometabolic-related news items have been observed from Lilly, Abbott, and NeuroBo. Below, FENIX provides highlights and insights for the respective news items.